MELBOURNE, AUSTRALIA / ACCESSWIRE / May 13, 2015 / Propanc Health Group Corporation (PINKSHEETS: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, announced today that it has retained Maxim Group LLC, a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Maxim will focus on assisting Propanc in its strategies for maximizing shareholder value through its full scope of investment banking services, including pursuing a listing of the Company's common stock on a nationally recognized exchange.
"I am pleased to engage the services of a leading investment bank like Maxim," said James Nathanielsz, Propanc's Chief Executive Officer. "We believe that partnering with Maxim will assist with fast tracking the strategic plans and vision we have for the Company. I look forward to working closely with the entire Maxim team."
"We are delighted to partner with Propanc in the financial and value creation components of its corporate strategy through our full-service investment banking capabilities," said Karl Brenza, Head of the Capital Growth Advisory Group of Maxim Group. "The combination of an experienced management team, existing growth prospects, large market opportunity and strong IP portfolio gave us the confidence to partner with Propanc. We look forward to working with management to assist with strategic planning, developing strategic partnerships, advising on potential acquisitions and introducing the company to the investment community."
About Maxim Group:
Maxim Group LLC is a leading full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed income and derivative sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA), Securities Insurance Protection Corporation (SIPC), NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
About Propanc:
We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings
Contact:
Regal Consulting
Tel: 702 - 575 - 9157
SOURCE: Propanc Health Group Corporation